Resverlogix

The future of drug development Resverlogix is committed to developing epigenetic therapies for the benefit of patients with chronic disease. Their current clinical program focuses on advancing their lead compound (apabetalone) and evaluating its therapeutic potential in the treatment of vascular disease and COVID-19. Resverlogix Corp. (“Resverlogix” or the “Company”), founded in 2001 by Donald McCaffrey …

The post FOX – Resverlogix: Dedicated to Improving the Lives of Patients with Chronic Illnesses appeared first on BTV News.